Nebivololo Zentiva (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivololo Zentiva, is a beta‑blocker presented as an oral tablet for oral use. It is employed to treat essential hypertension and, when indicated, heart failure in adult patients. GNH USA supplies Nebivololo Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivololo Zentiva is a beta‑blocker that acts on the cardiovascular system to control blood pressure and support cardiac function. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure (when indicated): improves ventricular filling and reduces symptoms of congestion.

Nebivololo Zentiva may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate discomfort often occurring early in therapy. - Dizziness or light‑headedness: related to blood pressure lowering. - Fatigue or tiredness: reduced cardiac workload may cause transient tiredness. - Nasal congestion: mild upper‑respiratory irritation. - Bradycardia: slower heart rate, usually asymptomatic.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: significant drop in blood pressure causing fainting. - Bronchospasm: especially in patients with reactive airway disease. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Cardiac function assessment: evaluate for underlying conduction abnormalities. - Asthma or COPD caution: β1‑selectivity reduces but does not eliminate risk of bronchospasm. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivololo Zentiva can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: may cause additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increase plasma levels and risk of cardiac depression. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Diuretics: combined effect may lead to excessive blood pressure reduction. - Clonidine: abrupt withdrawal can cause rebound hypertension; monitor when combined.